Probody therapeutics for targeting antibodies to diseased tissue.
Probodies are proteolytically activated antibodies engineered to remain inert until activated locally in diseased tissue. In principle, any therapeutic antibody can be converted into Probody™ form. In this perspective, we highlight the emerging therapeutic potential of the Probody approach in the form of conventional IgG-based Probodies as well as in the form of 'empowered Probody' formats such as Probody-drug conjugates.
CytomX Therapeutics, Inc. , 343 Oyster Point Boulevard, South San Francisco, CA 94080 , USA henry@cytomx.com.
Krishna R
KR
Polu
Henry B
HB
Lowman
D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000941:Antigens / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000378:metabolism / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000379:methods*; D011355:Prodrugs / Q000378:metabolism / Q000627:therapeutic use*; D015202:Protein Engineering
D018033:Antibodies, Bispecific; D000941:Antigens; D018796:Immunoconjugates; D007074:Immunoglobulin G; D011355:Prodrugs
EGFR; Jagged; antibody; antibody–drug conjugate; bispecific antibody; chimeric antigen receptor – T cells; probody; protease